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The outcome of familial
adenomatous polyposis in
the absence of a polyposis
registry
to reduce the risk of cancer of the rectum following
colectomy and i1eorectal anastomosis. Worldwide, however,
it is likely that most patients with FAP have no contact with
a registry. We have therefore studied the outcome of
patients managed at a single institution, where screening
programmes have been conducted sporadically by individual
clinicians and no formal registry exists.
P. A. Goldberg, M. V. Madden, E. du Toit, S. Bailey,
M. Torrington, W. H. Raynham Method
From 1964 to 1990, 70 patients with familial adenomatous
polyposis were diagnosed at an institution without a
polyposis registry. Those with symptoms at diagnosis
were older (mean 34 v. 24 years) and more often had
large-bowel cancer (7/30 v. 1/30, 23% v. 3%). The
introduction of systematic screening significantly
increased the number of cases diagnosed annually, from
2,3 to 5 per year, reduced the median age at diagnosis
from 29 to 21 years and increased the proportion of cases
diagnosed without symptoms from 52% to 90%. A
colectomy with an ileorectal anastomosis achieved a low
incidence of rectal cancer at 20 years (1/15,7%) despite
imperfect follow-up and annual sigmoidoscopy in only
40%. However, bowel cancer caused at least 35% of all
deaths and 62% of deaths due to a known cause. A
registry which maintained a screening programme should
therefore prevent most large-bowel cancers and improve
the life expectancy of patients with familial adenomatous
polyposis who are managed at this institution. It might
also refine the current method of screening by
sigmoidoscopy alone, by facilitating the use of
ophthalmoscopy and blood tests for DNA markers.
S Afr Med J 1995; 85: 272-276.
Familial adenomatous polyposis (FAP) almost always leads
to large-bowel cancer unless prophylactic surgery is
performed. The results of treating large numbers of patients
with FAP are usually reported from polyposis registries. Such
registries have two main functions. Firstly they identify,
among relatives of patients, those who have the disease and
will benefit from surgery to prevent large-bowel cancer.
Secondly, registries improve follow-up after surgery in order
Patients with FAP were identified from hospital computer
records of discharge diagnoses, the records of the
Department of Pathology and the records of surgeons with
an interest in the disease. All the patients managed at this
hospital were included in the study. Many had previously
been described in publications from the hospital.,,2 Fami.lial
adenomatous polyposis was diagnosed if several adenomas
were proven in patients with more than 100 polyps in trie
large bowel. The clinical details were obtained from the case
notes and the patients were traced to establish their sta'tus.
The first patient in the present series was identified in 1964.
From 1964 to 1974 a research assistant and a surgeon
traced members of some but not all families for screening
and systematic follow-up. This system then lapsed until
January 1988 after which screening was offered
systematically to family members at risk for the disease.
The Chi-squared test with Yates' correction was used to
compare proportions for large samples and Fisher's exact
test for small samples. Normally distributed data were
compared by Student's Hest. Variables not normally
distributed were compared with Wilcoxon's signed rank test.
Results
Over the 26 years, 70 patients with FAP were seen (35 men).
Thirty-five were white and 35 of mixed race. None was
black. Seven patients had no family history of polyposis and
in 2 the family history was unknown. The remaining 61
patients were from 8 families. In 60 patients it was known if
symptoms had been present at diagnosis, and the 30
patients with symptoms had a significantly higher
prevalence of large-bowel cancer at diagnosis and were on
average 10 years older than the asymptomatic patients
(Table I).
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In all, 99 operations were performed on 67 patients (1,5
operations per patient) (Fig. 1). The remaining 3 patients
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refused both surgical treatment and follow-up; 2 were lost to
follow-up, while the other died of colon cancer 6 years after
diagnosis aged 55 years. The most common operation
performed to prevent large-bowel cancer was a colectomy
with an ileorectal anastomosis, in 58 patients. The mean age
at this operation was 27 years (median 24 years, standard
deviation 10). One patient had a prior colostomy for an
obstructing carcinoma of the descending colon. Of these
patients 15 (26%) subsequently had at least one other
operation for FAp, excluding fulguration of rectal polyps,
during a median follow-up period of 10 years. Two of these
patients and 2 unoperated patients underwent ileo-anal
pouch procedures. Two of these 4 patients later had their
ileal pouch removed because of incontinence for which no
organic cause could be found. Two of 58 patients (3%) had
their colectomy and ileorectal anastomosis revised to a
proctocolectomy with an ileostomy, 1 for rectal cancer after
12 years and the other for multiple large rectal polyps with
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Fig. 2. Incidence of carcinoma of the rectal remnant after
ileorectal anastomosis (with 95% confidence limits).
The duration of follow-up of all 70 patients is shown in
Fig. 3. Nine were lost to follow-up after 1, 1, 10, 10, 10, 12,
21, 23 and 24 years (mean 11 years) respectively, while of
the remainder 14 have died. The cause of death is unknown
in 5 patients, and 1 died of ischaemic heart disease. The
remaining 8 patients (57%) died of FAP: 6 of carcinoma of
the large bowel (present at diagnosis in 5), 1 patient of
cancer of the duodenum and the other of a desmoid that
caused perforation of the small bowel. Gastroscopy with an


















Mean = 11 years
Median = 4 years
Fig. 1. Operations performed on all patients. (The number of
operations is in brackets where patients had more than one
procedure of the same type.)
Histological material from the first operation could be
reviewed in 59 of the 67 operated patients. Fifty-one had
adenomas and the remaining 8 (16%) had cancer (2 Dukes
A, 4 Dukes C and 2 residual intra-abdominal disease); 4 of
the latter were alive 5 years later. Because patients were
followed up by several different surgeons after colectomy
and i1eorectal anastomosis, it was difficult to establish how
often the retained rectum was examined. Consequently
reliable data were available for 22 patients, of whom only 9
(40%) had undergone rigid sigmoidoscopy at least once a
year. Of 15 patients who were followed up for 20 years
after colectomy and i1eorectal anastomosis, only 1
developed rectal cancer (7%,95% confidence interval
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Fig. 3. Duration of follow-up from diagnosis to last visit (all
patients).
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Table 11. Changes in number and age of patients diagnosed, and
in proportions with symptoms or with cancer, after introduction
of a screening programme
FAP is one of very few diseases in which diagnostic
screening makes it possible to prevent cancer. In this series
cancer was not present in any of the 10 patients identified
through the recent screening programme, while there were 8
patients with cancer (13%) among the 60 cases diagnosed
during an earlier period when screening was practised only
adenomatous polyps in 4, of whom 1 had an antrectomy.
Five patients have had retention polyps. No duodenal polyps
were found. A systematic screening programme for family
members was resumed in 1988 and this was accompanied
by three statistically significant changes. The median age at
diagnosis fell, the number of new cases annually rose and
the proportion without symptoms at diagnosis increased.
Since the screening programme began no patients have
developed cancer before diagnosis (Table 11).
The outcome of all 70 patients is summarised in Table Ill.
Table Ill. Outcome in 70 patients with FAP
Refused surgery 3
died, large-bowel cancer 1
lost after 0,5 yrs (age 39) & 24 yrs (age 54) 2
Total colectomy and ileorectal anastomosis 58
Cancer at colectomy 2
died, large-bowel cancer
lost after 10 yrs (age 50)
No cancer at colectomy 50
died, duodenal cancer 1
died, ischaemic heart disease 1
died, desmoid perforation 1
died, unknown cause 2
lost after 1 yr (age 41), 2 yrs (age 19)
& 23 yrs (age 56) 3
well 42
Histology of colectomy specimen not reviewed 6
died, rectal cancer after 12 years
lost after 10 yrs (age 35), 11 yrs (age 35),
12 yrs (age 30) & 21 yrs (age 42) 4
well 1
Other operations 9
died, large-bowel cancer 3
died, unknown cause 3
well 3
intermittently (Table 11). However, this small difference in
cancer incidence underestimates the true value of diagnostic
screening. More representative data from registries covering
three geographically defined areas (Finland, The Netherlands
and the northern region of the UK) have shown cancer in
32 - 62% of symptomatic patients compared with 0 - 9% of
those screened.3-' The Finnish registry has also shown that if
the disease was diagnosed by screening, a patient's
. probability of survival after the age of 30 years improved
significantly, compared with patients not diagnosed by
screening.
The traditional method of screening involves examination
of the rectum for polyps with a rigid sigmoidoscope.
Although a fibre-optic endoscope provides a clearer and
more extensive view the examination is more complex and
costly, so screening by colonoscopy is only important in the
very rare families whose polyps develop above an
unaffected rectum.6 Endoscopy is now being .~
complemented, but not replaced, by alternative methods of
screening. The molecular genetic technique of testing DNA
from blood samples holds most promise but other mett16ds
which have been used are examination of the optic fundi,
and radiography of the jaw.
The first tests performed on DNA used markers for unique
fragments of DNA which were known to lie near the gene.
The gene itself has recently been located;'-· it seems to
cause the disease by different mutations in different families.
The diagnostic tests compare DNA from affected and
unaffected family members, which means that the technique
is useless in a family where the disease is due to a new
mutation and only 1 affected subject is available. For the
same reason it is seldom useful in families with few living
members although DNA from the formalin-fixed tissue of
dead relatives has been used.'o At present DNA probes
seem to be useful in about 50% of families.",12 They allow
subjects to be divided into those at low or high risk of
developing the disease. Definition of a subject's risk is
helpful because it allows sigmoidoscopic screening to be
done less often in some patients and more often in others.
In addition to the use of DNA markers, the risk can also be
estimated by examining the optic fundi for the lesion
characteristic of FAP, congenital hypertrophy of the retinal
pigment epithelium (CHRPE)." CHRPE is easily missed by
conventional ophthalmoscopy and best identified by indirect
retinoscopy; an interested ophthalmologist is therefore
needed. The finding of four or more CHRPE lesions has
been reported as identifying 54 (88%) of 66 affected
individuals.'·
There are therefore several ways of estimating the risk of
FAP gene carriage in a subject who has not developed rectal
polyps. Each test provides an independent estimate of the
risk of carrying the gene and these estimates can be
combined to calculate the overall risk very accurately. It is
simplest, although not very accurate, to calculate the risk
from the person's age at a sigmoidoscopy which shows no
polyps, since these appear with increasing frequency as
affected subjects grow older. For example, if polyps are still
absent by the age of 24 years the risk of being affected is
below 10%,15 The findings on sigmoidoscopy and
retinoscopy can be used together, or combined with the
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radio-opaque jaw lesions are also common in FAP and the
findings of jaw radiographs, although not widely used,
further increase the value of the combined tests.'6
In South Africa individual surgeons treat most patients
with FAP and there is no polyposis registry. To what extent
should the new diagnostic tests change their approach to
patients and their families? It is now theoretically possible to
estimate the risk for most family members quite accurately
at an early age, but in practice this cannot be done without
a clinical geneticist, an enthusiastic ophthalmologist and,
ideally, a molecular genetics service. In any case, even
precise risk estimates are likely to cause quite small
changes in management. For example, the usual interval
between sigmoidoscopic examinations is 2 years, starting
from the early teens,17 and it has been suggested that for
low-risk persons (risk < 5%) this interval can be doubled.'2
In addition, if by the age of 40 years no.polyps have been
found, the overall risk will have fallen to about 0,1% and
screening of these subjects can be stopped." However,
some surgeons stop screening before this age in any case."
Conversely, in those at high risk or whose category cannot
be defined, the 2-year interval between examinations should
probably be maintained, perhaps continuing every 5 years
after 40 years of age."
The main aim of treating patients with FAP is to prevent
large-bowel cancer. How effectively was this achieved at our
hospital? The usual prophylactic operation is a colectomy
with an ileorectal anastomosis'6 and the major objection to it
is that cancer may develop in the remaining rectum. The
frequency of rectal cancer reported 20 years after the
operation ranges widely, from 9% to 59%.''''< However, in
this study only 1 of 15 patients (7%) developed rectal cancer
after 20 years. This low incidence is curious because in
most of our patients the rectal remnant was not examined
regularly for polyps. The probable explanation is that the age
of the rectum and not the age at colectomy determines the
risk of rectal cancer. Twenty years after colectomy our
patients (like those at St Mark's Hospital) had a mean age of
47 years and a very similar incidence of rectal cancer (7%
compared to 9% respectively). Patients who underwent the
same operation at the Mayo Clinic had a much higher
incidence of cancer (38%) after 20 years20 but had been, on
average, 9 years older at colectomy.25 Further support for the
concept that the age of the rectum determines the risk of
rectal cancer after an i1eorectal anastomosis comes from the
finding that the patients from St Mark's Hospital have
experienced a substantial increase in the probability of rectal
cancer after the age of 50 years.26
The alternative operation to a colectomy and ileorectal
anastomosis involves a colectomy and the construction of
an ileo-anal pouch. Only 4 (6%) of our patients had this
done and 2 of these now have a permanent stoma.
However, the functional outcome reported after ileo-anal
pouch operations is generally satisfactory2J.29 although few
surgeons consider it the operation of choice to prevent
large-bowel cancer.'·
Foregut cancer is likely to become a major cause of death
in patients in whom surgery prevents colorectal cancer.30.32
However, this occurred in only 1 of our patients who died of
duodenal cancer which was diagnosed when liver
metastases were present. It had not been diagnosed during
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an examination with an end-viewing duodenoscope 6
months previously. Furthermore, the apparent absence of
duodenal adenomas in all 18 of our patients who were
examined suggests that an end-Viewing instrument may not
be adequate for detecting them. A study of 102 cases with a
side-viewing duodenoscope to take systematic biopsies and
photographs identified duodenal adenomas in 94 of 102
duodenal biopsies (94%) and gastric adenomas in 6 of 73
gastric biopsies (8%).2' The absolute risk of duodenal and
ampullary cancer combined has been reported as 1/1 698
person-years of observation31 so it seems reasonable to
ignore most duodenal polyps. However, severe dysplasia in
a duodenal polyp is difficult to manage since a prophylactic
pancreaticoduodenectomy is dangerous and endoscopic
destruction of adenomas may not prevent cancer. Screening
endoscopy has been recommended29,3' but seems illogical
as long as there is no appropriate treatment for duodenal
polyps.
While FAP has been reported in South African blacks,33.,.
no cases have been diagnosed at our hospital. One reason
may be the founder effect that causes a high incidence in
white immigrants, as the first affected individual in one of
our families is thought to have arrived from Holland in about
1685. Another reason is that until recently the hospital has
served a population of predominantly mixed or Caucasian
descent.
We conclude that in our setting family screening has
reduced the incidence of cancer when FAP was diagnosed,
and a colectomy with an ileorectal anastomosis has been
surprisingly effective in preventing large-bowel cancer.
Therefore a registry which facilitates early diagnosis and
prophylactic surgery may well prove cost-effective. It should
help surgeons manage members of polyposis families more
appropriately, as collaboration with clinical and molecular
geneticists is becoming increasingly important.
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Non-invasive management
of organic impotence
F. J. L. Kaplan, N. S. Levitt, P. J. d'E. Stevens,
C. Phillips
Objective: To establish the efficacy of a vacuum device
(ErecAid) in the management of organic impotence.
Design: Cohort study; questionnaire before and after a
6-month study period.
Setting: Groote Schuur Hospital, Cape Town.
Participants: A total of 19 men with organic impotence,
8 diabetic and 11 with previous pelvic surgery or
radiotherapy
Intervention: Vacuum device (ErecAid, Osbon Medical
,-'
Systems).
Outcome measure: Efficacy of ErecAid. •
Results: Six of 8 diabetics and 6 of 11 non-diabetics
reported successful intercourse, while 16 of the
participants would recommend the device to others.
Some difficulty with the device was experienced by 11
and only 9 described an increase in self-esteem.
Conclusion: Although some difficulties may be
experienced in the use of the ErecAid, it clearly has a role
to play in the management of patients with organic
impotence, who ideally should be able to select their
preferred form of therapy.
S Afr Med J 1995; 85: 276-278.
Erectile dysfunction, most frequently psychogenic in nature,
is commonly encountered in clinical practice, affecting
approximately 10% of the adult male population.' However,
a number of conditions, including spinal cord injuries,
myelopathies and diabetes meliitus are associated with
organic impotence, with 35 - 50% of diabetic men being
affected!·3
Increased Willingness to report on sexual dysfunction, and
an ageing population seeking to maintain quality of life and
relationships, have resulted in considerable interest in the
treatment of impotence. Real advances have been made in
this area, including intracorporeal injections of papaverine
and prostaglandin E" and prosthetic surgery. These may,
however, be associated with problems such as long-term
penile fibrosis with intracorporeal injections,' prolongation of
the effect of papaverine leading to priapism, and poor
response to prostaglandin E, in patients with disorders of
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